I-Mab ADR (IMAB): Price and Financial Metrics


I-Mab ADR (IMAB)

Today's Latest Price: $49.52 USD

0.24 (-0.48%)

Updated Jan 15 4:00pm

Add IMAB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IMAB Stock Summary

  • I-Mab's stock had its IPO on January 17, 2020, making it an older stock than merely 0.23% of US equities in our set.
  • With a price/sales ratio of 156.64, I-Mab has a higher such ratio than 97.37% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, I-Mab is reporting a growth rate of 266.84%; that's higher than 94.66% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to I-Mab are XAIR, ACRS, HTBX, MRKR, and BCDA.
  • Visit IMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.i-mabbiopharma.com.

IMAB Stock Price Chart Interactive Chart >

Price chart for IMAB

IMAB Price/Volume Stats

Current price $49.52 52-week high $59.14
Prev. close $49.76 52-week low $9.30
Day low $48.76 Volume 175,600
Day high $51.48 Avg. volume 308,260
50-day MA $41.25 Dividend yield N/A
200-day MA $32.18 Market Cap 2.83B

I-Mab ADR (IMAB) Company Bio


I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.


IMAB Latest News Stream


Event/Time News Detail
Loading, please wait...

IMAB Latest Social Stream


Loading social stream, please wait...

View Full IMAB Social Stream

Latest IMAB News From Around the Web

Below are the latest news stories about I-Mab that investors may wish to consider to help them evaluate IMAB as an investment opportunity.

I-Mab Announces Upcoming Participation at January Conferences

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in January. Details of the conferences and management presentation are as follows:

Yahoo | December 23, 2020

I-Mab's (NASDAQ:IMAB) Intrinsic Value Is Potentially 23% Below Its Share Price

How far off is I-Mab ( NASDAQ:IMAB ) from its intrinsic value? Using the most recent financial data, we'll take a look...

Yahoo | December 21, 2020

I-Mab Added to Nasdaq Biotechnology Index

SHANGHAI and GAITHERSBURG, Md., Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab's American Depositary Shares (ADS)…

PR Newswire | December 14, 2020

Is IMAB A Good Stock To Buy Now?

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

Yahoo | December 11, 2020

I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced the advancement of…

PR Newswire | December 4, 2020

Read More 'IMAB' Stories Here

IMAB Price Returns

1-mo 24.33%
3-mo 21.88%
6-mo 65.18%
1-year 296.16%
3-year N/A
5-year N/A
YTD 5.03%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7721 seconds.